News
-
-
-
-
-
-
PRESS RELEASE
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
OSE Immunotherapeutics reports unaudited full year 2025 financial results and Q1 2026 cash position. Cash runway unchanged till early Q4 2026. Filing of 2025 Registration Document postponed to May 28, 2026 -
-
-
-
PRESS RELEASE
Route1 Reports Fiscal Year 2025 Results and Continued Transition Toward Recurring, Lifecycle-Based Revenue
Route1 Inc. announces fiscal 2025 financial results focused on recurring support and services revenue growth, operational improvement capabilities, ALPR deployment, and transition to embedded participant in operational performance